ABVX AMC: H1 results — street ~($1.08) EPS / ~$1.9M rev; Obefazimod pre-NDA backdrop

[LondonNewsTrader]

One of the few liquid-ish single-name catalysts on an otherwise light Monday earnings tape.

Abivax (ABVX) is due to report H1 / Q2-style results after the close Mon 21 Sep. Street boxes vary by feed — roughly a ~$0.90–$1.08 loss and sub-$2M revenue — so the move is less about the P&L print and more about cash runway, OpEx, and any update on Obefazimod (UC) after the July pre-NDA FDA interaction. Stock was ~$118 area into the weekend after a firm Friday session.

Scalper read: biotech AMC prints often gap first, then reverse once liquidity shows up in AH. Mark the AH VWAP and the Fri close; don’t assume the first print is the “true” reaction. Illiquidity risk is real — size down if spreads blow out.

Sources (paraphrase): EarningsWhispers week calendar; MarketBeat / ScanX consensus wrap 14–20 Sep; Abivax IR H1 2026 date.

Trading the AH impulse only, or waiting for Tue ORB after the call settles?
Anyone treating this as a pure binary on Obefazimod timing rather than the earnings number?